Over the past 50 years, a trend has been reported toward earlier pubertal development in girls, with the implication that early maturation may lead to adverse social and medical conditions, including cancer and diabetes ([@b20-ehp-118-1039]). Race, obesity, and genetics are likely determinants of pubertal timing, but hormonally active environmental exposures may also play a role ([@b13-ehp-118-1039]). Widespread exposure exists to such environmental agents. Children and minorities often have higher exposures, as demonstrated by urinary concentrations of many environmental biomarkers, compared with adults and whites \[[@b5-ehp-118-1039]\]. Specific chemicals that behave like estradiol include a number of phenols, such as bisphenol A. They act as hormone agonists in animal models of reproductive development, accelerating pubertal development. However, phytoestrogens and phthalates have both agonist and antagonist effects in animals, likely related to alternative mechanisms, dose levels, and exposure timing ([@b18-ehp-118-1039]).

The Breast Cancer and Environment Research Centers (BCERC) are a consortium established by the National Institute of Environmental Health Sciences and The National Cancer Institute to elucidate influences of environmental factors on timing of pubertal development in girls. For this purpose, we evaluated exposure using concurrent urinary biomarkers representing three classes of environmental agents in relation to breast and pubic hair development among the girls in this cohort. Biomarkers were selected based on a pilot study that revealed a wide range of values and high detectability in our cohort ([@b27-ehp-118-1039]). We hypothesized that phenols would be associated with earlier puberty, that phthalate biomarkers would be related to later pubertal timing, that phytoestrogens would be associated with later breast development, and that associations could be modified by obesity.

Materials and Methods
=====================

Study population
----------------

The BCERC epidemiology project is a longitudinal study of girls enrolled at 6--8 years of age and followed through puberty. It is part of a consortium of four centers with transdisciplinary research collaborations integrated across biologic, epidemiologic, and community outreach projects. Enrollment of 1,239 girls during 2004--2007 occurred at three sites: Mount Sinai School of Medicine (MSSM), which recruited in East Harlem in New York City; Cincinnati Children's Hospital (Cincinnati), which recruited in the greater Cincinnati, Ohio, metropolitan area, and through the Breast Cancer Registry of Greater Cincinnati; and Kaiser Permanente Northern California (KPNC), which recruited members of the KPNC Health Plan in the San Francisco Bay Area. All sites obtained informed consent from parent or guardian and independently verified child assent, approved by the institutional review boards at each institution and at the CDC. Eligibility included age, female sex, no underlying endocrine medical conditions, and at MSSM, black or Hispanic race/ethnicity.

Data collection
---------------

A questionnaire was completed by the parent or guardian of the girl (usually the mother) that included medical history, product use and exposures, and demographic variables. Parents or guardians identified the girls as black, white, Asian, or other, and ethnicity as Hispanic or non-Hispanic. We assessed age, weight, height, breast and pubic hair stages at the visit when urine was collected (visit 1) and approximately 1 year later (visit 2). Visits 1 for MSSM and KPNC were at baseline. Visit 1 for Cincinnati is defined for this analysis as the visit when urine was collected, which was 6 months after the first baseline visit. Visit 2 was approximately 1 year later \[details in Supplemental Material, Table 1 (doi:10.1289/ehp.0901690)\]. At each visit, breast (B1--B5) and pubic hair (PH1--PH5) stages were assessed by inspection and palpation. Examiners were trained and tested by a master clinician, following a written protocol with photographs that demonstrated the maturation stages ([@b3-ehp-118-1039]; [@b24-ehp-118-1039]). Inter-rater evaluations were conducted by one pediatrician. The kappa statistic was 0.67, indicating substantial agreement; concordance was 87% (117/127 among 39 examiners) ([@b3-ehp-118-1039]). Height and weight were measured using calibrated scales and stadiometers at each visit. Age-specific (in months) and sex-specific body mass index percentiles (BMI%) were calculated based on CDC growth charts ([@b4-ehp-118-1039]). Pubertal stages and BMI% distribution at visit 1 were similar among girls with visit 2 breast stages (*n* = 985) and without (*n* = 166) visit 2 data; however, girls without visit 2 data were more likely to be black or Hispanic, of lower socioeconomic status, and from MSSM ([Table 1](#t1-ehp-118-1039){ref-type="table"}).

Urinary biomarker measurements
------------------------------

Samples collected at visit 1 were analyzed at the National Center for Environmental Health laboratories at CDC for nine phthalate metabolites \[*n* = 1,149; monoethylphthalate (MEP), mono-butyl phthalate, mono-*iso*-butyl phthalate, mono-benzyl phthalate, mono-3-carboxypropyl phthalate, mono-2-ethyl-5-carboxypentyl phthalate, mono-(2-ethyl-5-hydroxylhexyl) phthalate, mono-(2-ethyl-5-oxohexyl) phthalate, and mono-(2-ethylhexyl) phthalate (MEHP)\], seven phenols (benzophenone-3, bisphenol A, 2,5-dichlorophenol, triclosan; *n* = 1,149; methyl-, butyl-, and propyl- parabens, *n* = 1,059), and three phytoestrogens (daidzein, genistein, enterolactone; *n* = 1,150). Parabens were not measured early in the study. At least one urinary biomarker measurement was available among 1,151 girls, 985 with breast stages. We substituted limit of detection (![](ehp-118-1039e1.jpg) for results below the LOD. Adjustment for urine dilution was accomplished using creatinine, to account for difference in sampling (spot specimens at MSSM and KPNC, early-morning samples at Cincinnati) and interindividual variation in urine dilution. We included log-creatinine in models using continuous log-biomarker variables, and we created quintile cut points from creatinine-corrected concentrations (micrograms per gram creatinine). As previously described, to reduce multiple comparisons we combined the phthalate metabolites into two groups that represent similar sources and similar biologic activity, low- (\< 250 Da) and high-molecular-weight (\> 250 Da) phthalate metabolites (low MWP and high MWP) \[details in Supplemental Material, Table 2 (doi:10.1289/ehp.0901690)\]. We expressed high MWP molar sum as MEHP (molecular weight 278) and the low MWP as MEP (molecular weight 194) so that units were the same as the other analytes (micrograms per liter). Similarly, a molar sum of the paraben metabolites was created (paraben sum) expressed as propyl paraben (molecular weight 180.2). Models with the individual phthalate and paraben metabolites were consistent with the molar sum variables. Results using di(2-ethylhexyl)phthalate (DEHP)-sum metabolites were almost identical to those for the high MWP, and they represented 75% ± 16% (mean ± SD) of the high MWP biomarkers. Therefore, only the latter models are presented.

Laboratory techniques and quality control protocols are identical to those reported previously in a pilot study ([@b27-ehp-118-1039]). Briefly, urine undergoes an automated cleanup with enzymatic deconjugation, followed by high-performance liquid chromatography-isotope dilution tandem mass spectrometry quantification ([@b15-ehp-118-1039]; [@b19-ehp-118-1039]; [@b30-ehp-118-1039], [@b29-ehp-118-1039]). In addition to the internal CDC quality control procedures, we incorporated approximately 10% masked quality control specimens (*n* = 101) from a single urine pool. The coefficients of variation (SD/mean concentration) were \< 10% for 13 analytes and were between 10% and 21% for the remaining six biomarkers.

Statistical analyses
--------------------

We examined relationships among pubertal stages, biomarkers, and study characteristics using nonparametric statistics (Spearman or Kruskal--Wallis) and multivariate linear regression (version 9.1.3; SAS Institute Inc., Cary, NC). We conducted multivariate analyses using Proc Genmod (SAS) with modified Poisson regression, which provides robust error variance estimates and is appropriate for outcomes that are not rare ([@b31-ehp-118-1039]). We computed prevalence ratios (PRs) and 95% confidence intervals (CIs) for any development \[breast stage 2 or higher (B2+); pubic hair stage 2 or higher (PH2+)\] versus no development (B1 or PH1) in relation to biomarker exposures. We considered covariates related to pubertal development and urinary biomarker concentrations. Variables that did not alter any biomarker estimate by \> 10% were backward-eliminated from the models. Excluding observations with very dilute biospecimens (*n* = 58 with creatinine \< 0.2 g/L) did not materially change biomarker estimates; therefore, they were retained in the analyses. We assessed the trend of estimates for biomarker quintiles using their ordinal values with the contrast option in Proc Genmod. Models with continuous log-biomarker variable were consistent with results of models using quintiles. We report results for pubertal stages assessed at visit 2, one year after urine collection, when the proportions with B2+ and PH2+ were greater and site variations were less pronounced. There were 985 girls with biomarkers and visit 2 breast stage and 967 with visit 2 pubic hair stages.

We hypothesized that exogenous exposures were likely to operate jointly with BMI, a strong endogenous hormonal risk factor for pubertal development ([@b14-ehp-118-1039]). This hypothesis was examined by adding to models an interaction term for the product of the biomarker variable (log-continuous or ordinal quintile values) times BMI dichotomized at the median of the age-specific percentiles in our study population (low BMI/high BMI).

Results
=======

BCERC cohort girls were 6--8 years of age and mainly black, Hispanic, and white race/ethnicities ([Table 1](#t1-ehp-118-1039){ref-type="table"}). Median ages differed by \< 0.5 years across the sites, being youngest at MSSM and oldest at Cincinnati at both visits. Every site had \> 20% blacks, but there were no whites from MSSM and very few Hispanics at Cincinnati. All characteristics including pubertal stages differed by site ([Table 1](#t1-ehp-118-1039){ref-type="table"}; *p* \< 0.01). Compared with normative national data for BMI, 65% of girls were above the 50th percentile at visit 1 (i.e., 15% more than expected), 32% were above the 85th percentile (overweight), and 17% were also above the 95th percentile (obese) ([@b4-ehp-118-1039]). BMI% was highest among MSSM (median 75th percentile of the norm) and lowest among Cincinnati girls (median 64th percentile).

As expected, the environmental biomarkers were detected in almost all of the urine samples \[Supplemental Material, Table 2 (doi:10.1289/ehp.0901690)\]. Overall, phenol median concentrations were \< 100 μg/L, and urinary phytoestrogen and phthalate biomarker medians were \> 400 μg/L. Geometric mean concentrations (micrograms per liter) of urinary exposure biomarkers are presented in [Table 2](#t2-ehp-118-1039){ref-type="table"} mutually adjusted for covariates. Benzophenone-3 (BP3), a sunscreen, was higher in samples collected in the summer and among white children, compared with blacks and Hispanics. 2,5-Dichlorophenol (2,5-DCP) was lower in whites and higher in MSSM participants; it is the metabolite of 1,4-dichlorobenzene used in mothballs and room deodorizers. Parabens are found as preservatives in many personal care products; their levels were higher among blacks and in samples collected in summer. Parabens often occur together with BP3 and low MWP in consumer products. Low-MWP biomarkers were higher in blacks and Hispanics than whites and Asians. The isoflavones daidzein and genistein, which are found in soy products, were somewhat higher among Asians. Enterolactone, a gut metabolite of lignans found in flax, beans, grains, and berries, tended to be higher among blacks and whites.

One year after urine samples were collected for biomarker measurements, breast development was present in 30% and pubic hair in 22% of girls ([Table 1](#t1-ehp-118-1039){ref-type="table"}). As shown in [Table 3](#t3-ehp-118-1039){ref-type="table"}, the frequency of any breast and pubic hair development increased or decreased across quintiles of most biomarkers, but the adjusted PRs were close to null. Low MWP had weak positive associations with both breast and pubic hair stages. For breast development, the adjusted PR was 1.06 (95% CI, 0.99--1.14; *p*-trend = 0.087) in the fifth versus first quintile. The isoflavones daidzein and genistein had weak inverse associations with breast stage; for daidzein, the adjusted PR was 0.96 for the fifth versus first quintile (95% CI, 0.90--1.02; *p*-trend = 0.061). Triclosan had a suggestive inverse association with pubic hair development, but the trend was not monotonic, and the CIs were similar for every quintile ([Table 3](#t3-ehp-118-1039){ref-type="table"}). An inverse relationship with pubic hair development was seen for high MWP.

Enterolactone modified the association of BMI with breast development. The proportion of low-BMI girls at pubertal stages B2+ increased from 15 to 20% across enterolactone quintiles (see note to [Table 4](#t4-ehp-118-1039){ref-type="table"}). Among girls with high BMI, the proportion in the first quintile (48% B2+) decreased to 25% B2+ in the fifth quintile. This inverse association among high-BMI girls supported our hypothesis, and it remained after further adjustment for covariates ([Table 4](#t4-ehp-118-1039){ref-type="table"}). The difference in the enterolactone PRs between low- and high-BMI groups suggests that higher enterolactone exposures may attenuate the BMI association. Specifically, in the first quintile of enterolactone in [Table 4](#t4-ehp-118-1039){ref-type="table"}, the PR for pubertal stage B2+ versus B1 was 1.34 (95% CI, 1.23--1.45) for high BMI compared with low-BMI girls, the referent. This difference, the "BMI association," diminished steadily so that in the fifth quintile of enterolactone, the PRs for B2+ versus B1 were comparable for low BMI and high BMI (PR = 1.14 and 1.20, respectively, with similar CIs) ([Table 4](#t4-ehp-118-1039){ref-type="table"}). Thus, breast development differed among low- and high-BMI girls with low enterolactone exposure, but development was similar at the highest exposure levels regardless of BMI. These enterolactone associations with breast stage were similar in models stratified by BMI and further adjusted for BMI%; results were also consistent by race/ethnicity and by site.

Apparent modification by BMI% of three other biomarkers in relation to pubertal stages could be explained by residual confounding of race or BMI% \[*p*-interactions \< 0.1; see Supplemental Material, Table 3 (doi:10.1289/ehp.0901690)\]. In addition, genistein had a borderline interaction, but neither BMI stratum exhibited a trend of the adjusted PRs across biomarker quintiles. 2,5-DCP exhibited a positive association with breast development among high-BMI girls (*p*-interaction = 0.071; *n* = 948; *p*-trend 0.009), but in models stratified by BMI% further adjusted for BMI%, the association among high-BMI girls was null. The resulting attenuated estimate was similar to that of the main effect model for 2,5-DCP shown in [Table 3](#t3-ehp-118-1039){ref-type="table"}. High MWP (*p*-interaction = 0.039) did not exhibit a dose--response relationship with breast development in low- or high-BMI groups (*p*-trends \> 0.80). BP3 exhibited patterns similar to those of enterolactone. The BP3 association with breast stage had a positive direction in low-BMI girls and an inverse relationship in high-BMI girls (*p*-interaction 0.088). However, no dose--response relationship was evident. In BMI-stratified models, among girls with low-BMI the adjusted PR was 1.08 for the fifth versus first quintile of BP3 (95% CI, 0.97--1.20; *p*-trend 0.15; *n* =4 69); in high-BMI girls the *p*-trend was 0.38 (not shown).

Discussion
==========

In this group of 1,151 girls, we examined concurrent exposures from three chemical classes that possess known or likely hormonal activity in relation to pubertal development. Biologically relevant levels of the biomarkers existed among girls in the cohort. Most biomarkers were ubiquitously detected, and maximal concentrations were in the range known to elicit effects experimentally (e.g., \> 10 μmol). Overall, biomarker concentrations were similar to those reported in the National Health and Nutrition Examination Survey (NHANES) for children 6--11 years of age ([@b5-ehp-118-1039]), as were those in the pilot study ([@b27-ehp-118-1039]). These urinary metabolites are derived from common personal and household products or dietary sources, and absorption may occur through ingestion, inhalation, or dermal routes ([@b17-ehp-118-1039]).

Associations of concurrent exposure biomarkers with breast and pubic hair development in these girls were not strong, but those observed were among the chemicals with greatest exposure levels. The strongest finding was attenuation by enterolactone exposure of the BMI association with breast development. Along with the inverse relationships of daidzein and genistein with breast development and high MWP with pubic hair stage, the results were consistent with our *a priori* hypotheses and the experimental literature. Comparable associations of phytoestrogens with breast stage were seen in an earlier small study ([@b26-ehp-118-1039]). Phytoestrogens including enterolactone are known to possess hormonal activity ([@b2-ehp-118-1039]). A protective effect for puberty might be consistent with counteracting the influence of obesity ([@b12-ehp-118-1039]) or by reducing adiposity ([@b6-ehp-118-1039]). In contrast, associations were positive, albeit very weak, for low MWP with both breast and hair development. It is not clear why low- and high-MWP metabolites could have opposite associations with developmental stages, yet various reports of such exposures in humans and animals show divergent hormonal associations, depending on timing and intensity of exposure or treatment and on rodent strain ([@b2-ehp-118-1039]; [@b18-ehp-118-1039]; [@b20-ehp-118-1039]; [@b22-ehp-118-1039]). In addition, patterns and density of ambient exposures no doubt differ for the low MWPs and high MWPs ([@b1-ehp-118-1039]).

Residual confounding or misclassification of exposures and outcomes remain possible explanations for our results. Collinearity of covariates, such as that among BMI, race/ethnicity, urinary creatinine, and urinary biomarkers and their variation by study site, are potential difficulties. We used methods with robust variance handling in an effort to minimize such problems. A potential explanation for the lack of strong associations is overadjustment of the models due to the inclusion of certain covariates ([@b9-ehp-118-1039]; [@b25-ehp-118-1039]). For example, BMI may be both a confounder and on the pathway between exposure and pubertal development. Considering the interrelationships among our variables, the models presented are the most appropriate. For our main analyses, we used creatinine-corrected biomarker concentrations to create quintile cut points. Creatinine correction may be inadequate for some or all analytes. However, we did not measure specific gravity, an alternate measure of urine dilution ([@b10-ehp-118-1039]; [@b16-ehp-118-1039]). Other methods, such as the regression normalization procedures ([@b11-ehp-118-1039]), may not be appropriate for all urinary metabolites. Besides exposure misclassification, there is potential error in the outcome measurement of pubertal stage because of inter-rater variability in pubertal stage assessment. Therefore, both exposure and outcome measurements may be subject to nondifferential misclassification bias, which would likely shift the estimates toward the null. Additional considerations, including genetic and racial differences in exposure and development, would require considerably larger sample size. We estimated that for the main effects we had adequate power (80%) to detect PRs of 1.1 in 479 girls, if B2+ or PH2+ were \> 20% in the fifth quintile (alpha 0.05), and a PR of 0.94 with 948 girls; these values are similar to the strongest associations we observed. Our effect estimates also may be conservative, because we used Poisson models instead of logistic regression models. For example, for the PR of 0.94 (95% CI, 0.88--1.00, high MWP and PH2+) in [Table 3](#t3-ehp-118-1039){ref-type="table"}, we computed an odds ratio (OR) of 0.60 (95% CI, 0.34--1.06). However, measures of association using ORs may be over- or underestimated ([@b31-ehp-118-1039]). Finally, some or all of our findings may be due to chance; \> 100 comparisons were made for the models presented in [Tables 3](#t3-ehp-118-1039){ref-type="table"} and [4](#t4-ehp-118-1039){ref-type="table"}. Associations of hormonal exposures in this study were small, which may be consistent with their relatively weak biological activity compared with endogenous hormones ([@b8-ehp-118-1039]; [@b22-ehp-118-1039]). Small effect estimates may be more realistic than those in previous studies that had small sample sizes ([@b26-ehp-118-1039]). There will be greater power to detect associations in longitudinal analyses that can also better reflect causal relationships than cross-sectional analyses; we plan to undertake such analyses as the cohort matures. The reports of delayed pubertal development in relation to blood lead concentrations in the NHANES population are informative for our findings, as the lead effects appear stronger than those we observed. [@b21-ehp-118-1039] observed among black girls an OR of 0.62 (95% CI, 0.41--0.96, multivariate adjusted) for PH2+ versus PH1 among girls with blood lead \> 3 μg/dL, quartile of exposure, compared with those having blood lead \< 1 μg/dL, approximately the upper versus first quartile of their exposures. For the same NHANES population, [@b28-ehp-118-1039] found ORs for PH2+ of 0.27 (95% CI, 0.08--0.93) in the top exposure group (≥ 5 μg/dL) compared with ≤ 2 μg/dL blood lead. The proportion of PH2+ in the low exposure stratum was 81% versus 44% at high exposure. By comparison, the prevalence of PH2+ was 28% in the first compared with 20% in the fifth quintile of high MWP in [Table 3](#t3-ehp-118-1039){ref-type="table"}, and the adjusted PR was 0.94 (95% CI, 0.88--1.00). High-MWP medians were 7-fold different between these quintiles compared with 3-fold differences in the lead exposure categories.

An additional consideration is that the peripubertal period is likely not the only critical window of exposure for pubertal development. Both animal and epidemiology studies suggest that prenatal and perinatal exposures also exert effects on later development ([@b18-ehp-118-1039]; [@b20-ehp-118-1039]). Exposures during different windows may affect different molecular targets, including prenatal imprinting, the hypothalamic-pituitary axis, gonadotropin-releasing hormone neurons, hormone receptors, and aromatase action ([@b20-ehp-118-1039]). Effective exposure ranges for these mechanisms may also differ widely, that is, toxic equivalents. Environmental agents in our study are cleared rapidly; it is possible that a single biomarker measurement is inadequate to quantify exposure relevant to pubertal development. However, single measurements of urinary biomarkers of phenols and phthalates were fairly representative of 6--12 months of exposure in children this age ([@b23-ehp-118-1039]), likely because of common use and continuous exposure to many chemicals. Time-integrated multiple childhood exposure measures prenatally and prepubertally may be possible in alternate study designs. An important additional direction is to evaluate multiple exposures, including the extremes of exposure, multiple high exposures, early life exposures, and/or extremes of development (very late vs. very early changes) ([@b7-ehp-118-1039]).

As we have mentioned, these environmental biomarkers were considered important for pubertal development because their concentrations are higher and in some cases their bioassay potency is greater than commonly studied environmental agents such as lead and 1,1′-dichloro-2,2′-bis(4-chlorophenyl)ethylene (DDE). Although the suggestive associations we observed are small, within 10% of null, a small effect size could affect a significant proportion of the population because of the ubiquity of these exposures and by their high levels (micromolar) observed in urine of the BCERC cohort.
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###### 

Characteristics at visit 1 and by site for 1,151 girls with at least one biomarker value: BCERC cohort, 2004--2007 \[*n* (%)\].

  Variable                               All sites combined   MSSM         Cincinnati   KPNC
  -------------------------------------- -------------------- ------------ ------------ ------------
  Age at baseline (visit 1) (years)                                                     
   6.0--6.9                              293 (25.5)           153 (37.7)   71 (22.0)    69 (16.4)
   7.0--7.9                              571 (49.6)           131 (32.3)   148 (45.8)   292 (69.2)
   ≥ 8.0--9.4                            287 (24.9)           122 (30.0)   104 (32.2)   61 (14.5)
   Median age                            7.50                 7.25         7.64         7.41
                                                                                        
  Age at visit 2 (years)                                                                
   6.9--7.9                              245 (21.3)           105 (25.9)   65 (20.2)    75 (17.8)
   8.0--8.9                              478 (41.5)           97 (23.9)    133 (14.3)   247 (58.7)
   ≥ 9.0--10.6                           266 (23.1)           103 (25.4)   92 (28.6)    70 (16.6)
   Not seen including missing (1)        162                  101          32           29
   Median age                            8.50                 8.41         8.66         8.50
                                                                                        
  Child race/ethnicity                                                                  
   White                                 391 (34.0)           0 (0.0)      220 (68.1)   171 (40.5)
   Black                                 353 (30.7)           164 (40.4)   97 (30.0)    92 (21.8)
   Hispanic, non-black                   344 (29.9)           242 (59.6)   1 (0.3)      101 (23.9)
   Asian                                 53 (4.6)             0 (0.0)      4 (1.2)      49 (11.6)
   Other                                 10 (0.9)             0 (0.0)      1 (0.3)      9 (2.1)
                                                                                        
  BMI age- and sex-specific percentile                                                  
   \< 50th                               394 (34.2)           133 (32.8)   101 (31.3)   160 (37.9)
   50--85th                              388 (33.7)           114 (28.1)   132 (40.9)   142 (33.6)
   ≥ 85th                                369 (32.1)           159 (39.2)   90 (27.9)    120 (28.4)
                                                                                        
  Parent or guardian education                                                          
   ≤ High school                         342 (29.7)           236 (58.1)   29 (9.0)     77 (18.2)
   \> High school                        765 (66.5)           162 (39.9)   261 (80.8)   342 (81.0)
   Missing                               44                   8            33           3
                                                                                        
  Season of urine collection                                                            
   Spring (March--May)                   393 (34.1)           112 (27.6)   163 (50.5)   118 (28.0)
   Summer (June--August)                 322 (28.0)           94 (23.2)    48 (14.9)    71 (16.8)
   Fall (September--November)            213 (18.5)           90 (22.2)    64 (19.8)    168 (39.8)
   Winter (December--February)           223 (19.4)           110 (27.1)   48 (14.9)    65 (15.4)
                                                                                        
  Interval between visits 1 and 2                                                       
   \< 14 months                          893 (90.5)           239 (78.4)   288 (99.0)   367 (93.6)
   ≥ 14 months                           94 (9.5)             66 (21.6)    3 (1.0)      25 (6.4)
                                                                                        
  Breast stage at visit 1                                                               
   B1                                    943 (81.9)           317 (78.1)   237 (73.4)   389 (92.2)
   B2+                                   206 (17.9)           89 (21.9)    86 (26.6)    31 (7.4)
   Missing                               2                    0            0            2
                                                                                        
  Breast stage at visit 2                                                               
   B1                                    688 (59.8)           194 (47.8)   167 (51.7)   327 (77.5)
   B2+                                   297 (25.8)           111 (27.3)   124 (38.4)   62 (14.7)
   Not seen including missing (5)        166                  101          32           33
                                                                                        
  Pubic hair stage at visit 1                                                           
   PH1                                   979 (85.1)           334 (82.3)   275 (85.1)   370 (87.7)
   PH2+                                  151 (13.1)           71 (17.5)    43 (13.3)    37 (8.8)
   Missing                               21                   1            5            15
                                                                                        
  Pubic hair stage at visit 2                                                           
   PH1                                   756 (65.7)           216 (53.2)   230 (71.2)   310 (73.5)
   PH2+                                  211 (18.3)           88 (21.7)    61 (18.9)    62 (14.7)
   Not seen including missing (23)       184                  102          32           50
                                                                                        
  Total *n*                              1,151                406          323          422

###### 

Geometric means (95% CIs) of environmental urinary biomarkers at baseline examination in relation to covariates, mutually adjusted and for ln-urinary creatinine (1,102 girls with all characteristics, 2004--2007).

                                            Phenols (μg/L)                                                Phthalate monoesters, μg/L                                      Phytoestrogens (μg/L)                                                                                                                                                                                                                                                                                                                                                                                                                                     
  ----------------------------------------- ------------------------------------------------------------- --------------------------------------------------------------- --------------------------------------------------------------- ------------------------------------------------------------- ------------------------------------------------------------- --------------------------------------------------------------- --------------------------------------------------------------- --------------------------------------------------------------- ------------------------------------------------------------- ---------------------------------------------------------------
  Age at baseline exam (years)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
   6.0--6.9                                 33 (24--45)                                                   2.1 (1.8--2.4)                                                  13 (10--17)                                                     17 (13--23)                                                   78 (61--101)                                                  169 (145--199)                                                  183 (158--212)                                                  143 (106--194)                                                  66 (49--90)                                                   307 (248--381)
   7.0--7.9                                 28 (21--37)                                                   1.9 (1.7--2.2)                                                  14 (11--18)                                                     17 (13--23)                                                   63 (50--79)                                                   161 (140--186)                                                  178 (156--202)                                                  106 (81--139)                                                   49 (37--64)                                                   323 (267--390)
   ≥ 8.0                                    28 (20--38)                                                   1.8 (1.5--2.1)                                                  14 (11--19)                                                     17 (13--23)                                                   63 (48--81)                                                   156 (133--182)                                                  157 (136--182)                                                  112 (83--151)[\*](#tfn2-ehp-118-1039){ref-type="table-fn"}      50 (37--67)[\*](#tfn2-ehp-118-1039){ref-type="table-fn"}      320 (259--396)
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  Race/ethnicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
   White                                    51 (41--63)                                                   2.0 (1.8--2.3)                                                  6.0 (5.1--7.5)                                                  14 (11--17)                                                   39 (33--47)                                                   114 (102--127)                                                  179 (162--199)                                                  118 (96--146)                                                   56 (45--69)                                                   396 (341--461)
   Black                                    12 (10--15)                                                   2.2 (2.0--2.4)                                                  22 (18--26)                                                     16 (13--19)                                                   170 (143--201)                                                211 (190--233)                                                  150 (137--165)                                                  96 (79--116)                                                    40 (33--49)                                                   351 (306--403)
   Hispanic, non-black                      22 (17--27)                                                   2.1 (1.9--2.3)                                                  20 (17--24)                                                     15 (12--19)                                                   83 (69--99)                                                   190 (170--212)                                                  178 (160--197)                                                  80 (65--98)                                                     38 (31--47)                                                   273 (235--318)
   Asian                                    32 (20--52)                                                   1.5 (1.2--2.0)                                                  14 ( 9.0--21)                                                   14 (9.1--23)                                                  55 (37--82)                                                   117 (91--149)                                                   174 (139--219)                                                  203 (127--324)                                                  118 (74--188)                                                 269 (193--375)
   Other                                    52 (17--160)[\*\*](#tfn3-ehp-118-1039){ref-type="table-fn"}   1.9 (1.1--3.3)                                                  15 (5.5--38)[\*\*](#tfn3-ehp-118-1039){ref-type="table-fn"}     32 (11--90)                                                   46 (19--113)[\*\*](#tfn3-ehp-118-1039){ref-type="table-fn"}   211 (120--369)[\*\*](#tfn3-ehp-118-1039){ref-type="table-fn"}   182 (109--305)[\*](#tfn2-ehp-118-1039){ref-type="table-fn"}     133 (46--384)[\*\*](#tfn3-ehp-118-1039){ref-type="table-fn"}    47 (16--137)[\*\*](#tfn3-ehp-118-1039){ref-type="table-fn"}   311 (146--663)[\*\*](#tfn3-ehp-118-1039){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  BMI age-specific percentile at baseline                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
   \< 50th                                  31 (23--42)                                                   2.0 (1.7--2.3)                                                  13 (9.8--16)                                                    19 (15--26)                                                   70 (55--89)                                                   153 (132--178)                                                  180 (157--206)                                                  116 (87--153)                                                   53 (40--71)                                                   376 (308--460)
   50--85th                                 27 (20--36)                                                   2.0 (1.7--2.3)                                                  14 (11--18)                                                     15 (12--20)                                                   61 (48--78)                                                   157 (136--182)                                                  167 (146--192)                                                  121 (91--161)                                                   52 (39--69)                                                   345 (282--421)
   ≥ 85th                                   31 (23--42)                                                   1.9 (1.6--2.2)                                                  15 (12--20)                                                     17 (13--22)                                                   72 (57--93)                                                   177 (152--206)                                                  170 (148--196)                                                  121 (91--162)                                                   58 (43--77)                                                   245 (199--301)[\*\*](#tfn3-ehp-118-1039){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  Caregiver education                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
   12 years                                 24 (18--33)                                                   1.9 (1.6--2.2)                                                  15 (11--20)                                                     18 (14--24)                                                   63 (49--81)                                                   174 (149--203)                                                  178 (154--205)                                                  117 (87--157)                                                   55 (41--74)                                                   288 (233--356)
   ≥ 13 years                               36 (28--47)[\*\*](#tfn3-ehp-118-1039){ref-type="table-fn"}    2 (1.7--2.3)                                                    13 (10--17)                                                     16 (13--21)                                                   72 (58--90)                                                   151 (132--173)[\*](#tfn2-ehp-118-1039){ref-type="table-fn"}     167 (147--189)                                                  122 (95--158)                                                   54 (42--70)                                                   347 (289--417)[\*](#tfn2-ehp-118-1039){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  Study site                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
   MSSM                                     22 (16--30)                                                   2.3 (1.9--2.7)                                                  46 (34--60)                                                     15 (11--20)                                                   70 (54--92)                                                   201 (171--237)                                                  242 (209--281)                                                  89 (65--120)                                                    42 (31--57)                                                   287 (230--357)
   Cincinnati                               20 (14--28)                                                   1.9 (1.6--2.2)                                                  13 (9.6--17)                                                    28 (21--39)                                                   66 (50--88)                                                   163 (138--194)                                                  154 (131--180)                                                  135 (97--186)                                                   60 (43--82)                                                   252 (200--318)
   KPNC                                     58 (44--78)[\*\*](#tfn3-ehp-118-1039){ref-type="table-fn"}    1.7 (1.5--2.0)[\*\*](#tfn3-ehp-118-1039){ref-type="table-fn"}   4.7 (3.7--6.1)[\*\*](#tfn3-ehp-118-1039){ref-type="table-fn"}   12 (9.0--16)[\*\*](#tfn3-ehp-118-1039){ref-type="table-fn"}   66 (52--83)                                                   129 (112--149)[\*\*](#tfn3-ehp-118-1039){ref-type="table-fn"}   137 (120--157)[\*\*](#tfn3-ehp-118-1039){ref-type="table-fn"}   143 (109--188)[\*\*](#tfn3-ehp-118-1039){ref-type="table-fn"}   64 (49--84)[\*](#tfn2-ehp-118-1039){ref-type="table-fn"}      439 (361--534)[\*\*](#tfn3-ehp-118-1039){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  Season of urine collection                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
   Spring                                   20 (15--27)                                                   1.8 (1.5--2.0)                                                  13 (10--17)                                                     17 (13--22)                                                   66 (51--84)                                                   154 (132--179)                                                  169 (147--194)                                                  134 (101--178)                                                  64 (48--85)                                                   310 (253--380)
   Summer                                   125 (92--172)                                                 2.4 (2.1--2.8)                                                  13 (10--17)                                                     18 (14--24)                                                   93 (72--121)                                                  208 (177--243)                                                  185 (160--214)                                                  98 (73--132)                                                    45 (33--60)                                                   271 (219--335)
   Fall                                     22 (16--30)                                                   2.0 (1.7--2.4)                                                  18 (14--24)                                                     15 (11--21)                                                   54 (41--70)                                                   145 (123--171)                                                  175 (151--204)                                                  124 (91--170)                                                   57 (42--77)                                                   349 (280--436)
   Winter                                   14 (10--19)[\*\*](#tfn3-ehp-118-1039){ref-type="table-fn"}    1.6 (1.4--2.0)[\*\*](#tfn3-ehp-118-1039){ref-type="table-fn"}   13 (9.9--18)[\*](#tfn2-ehp-118-1039){ref-type="table-fn"}       18 (13--25)                                                   63 (48--83)[\*\*](#tfn3-ehp-118-1039){ref-type="table-fn"}    149 (126--176)[\*\*](#tfn3-ehp-118-1039){ref-type="table-fn"}   161 (138--188)                                                  125 (91--171)                                                   55 (40--76)[\*](#tfn2-ehp-118-1039){ref-type="table-fn"}      343 (273--430)

When any adjusted geometric mean differed from one or more of the others within a characteristic, the bottom value is marked with an asterisk. BMI% is sex- and age-specific ([@b4-ehp-118-1039]). Spring is March, April, May; other seasons follow sequentially. Paraben sum is the molar sum of methyl-, butyl-, and propyl-parabens, expressed as propylparaben (MW 180.2). Low MWP is the molar sum of MEP, MBP (monobutyl phthalate), MIBP expressed as MEP (MW = 194). High MWP is the molar sum of MBZP (mono-benzyl phthalate), MCPP \[mono(3-carboxypropyl) phthalate\], MEHP, MEOHP \[mono-(2-ethyl-5-oxohexyl) phthalate\], MEHHP \[mono-(2-ethyl-5-hydroxyhexyl) phthalate\], and MECPP \[mono(2-ethyl-5-carboxypentyl) phthalate\] expressed as MEHP (MW = 278). DEHP metabolite sum, which was 75 ± 16% of high MWP and had almost identical means, is omitted from the table. Details are in Supplemental Material, Table 2 (doi:10.1289/ehp.0901690).

*p* \< 0.05,

*p* \< 0.01.

###### 

PRs and 95% CIs for breast development stage (B2+ vs. B1) and pubic hair stage (PH2+ vs. PH1) in relation to urinary environmental biomarkers measured 1 year earlier. BCERC Cohort, 2004--2008.

                           Quintiles of creatinine-corrected biomarker concentrations (C)                                                                                   
  ------------------------ ---------------------------------------------------------------- ------------------- ------------------- ------------------- ------------------- -----------
  Breast development                                                                                                                                                        
  Phenols                                                                                                                                                                   
  BP3                                                                                                                                                                       
   Quintile median μg/gC   3.6                                                              11.1                30.4                93.6                867                 
   *n* B2+/*n* total       76/196                                                           65/197              64/196              52/197              40/196              
   PR (95% CI)             1 (Ref)                                                          0.96 (0.89--1.03)   0.96 (0.89--1.02)   0.91 (0.85--0.98)   0.87 (0.81--0.93)   \< 0.0001
   Adj PR (95% CI)         1 (Ref)                                                          1.00 (0.94--1.06)   1.01 (0.95--1.07)   0.99 (0.93--1.06)   1.01 (0.94--1.09)   0.847
  BPA                                                                                                                                                                       
   Quintile median μg/gC   1.0                                                              1.6                 2.4                 3.7                 8.7                 
   *n* B2+/total           69/196                                                           59/197              54/196              61/197              54/196              
   PR (95% CI)             1 (Ref)                                                          0.96 (0.90--1.03)   0.94 (0.88--1.01)   0.97 (0.90--1.04)   0.94 (0.88--1.01)   0.171
   Adj PR (95% CI)         1 (Ref)                                                          0.96 (0.90--1.02)   0.95 (0.89--1.01)   0.97 (0.91--1.03)   0.97 (0.91--1.03)   0.533
  2,5-DCP                                                                                                                                                                   
   Quintile median μg/gC   1.6                                                              4.0                 10.7                37.2                179                 
   *n* B2+/total           34/196                                                           51/197              62/196              74/197              76/196              
   PR (95% CI)             1 (Ref)                                                          1.07 (1.00--1.15)   1.12 (1.05--1.20)   1.17 (1.10--1.25)   1.18 (1.11--1.26)   \< .0001
   Adj PR (95% CI)         1 (Ref)                                                          0.99 (0.93--1.06)   0.97 (0.91--1.04)   1.04 (0.96--1.12)   1.02 (0.94--1.10)   0.416
  Triclosan                                                                                                                                                                 
   Quintile median μg/gC   2.6                                                              6.9                 15                  38                  170                 
   *n* B2+/total           57/196                                                           49/197              59/196              65/197              67/196              
   PR (95% CI)             1 (Ref)                                                          0.97 (0.90--1.04)   1.01 (0.94--1.08)   1.03 (0.96--1.10)   1.04 (0.97--1.11)   0.077
   Adj PR (95% CI)         1 (Ref)                                                          0.99 (0.93--1.05)   0.97 (0.92--1.03)   1.01 (0.95--1.07)   1.03 (0.97--1.10)   0.242
  Paraben sum                                                                                                                                                               
   Quintile median μg/gC   15                                                               36                  84                  198                 839                 
   *n* B2+/total           45/180                                                           50/181              58/181              45/181              68/180              
   PR (95% CI)             1 (Ref)                                                          1.02 (0.95--1.10)   1.06 (0.98--1.14)   1.00 (0.93--1.07)   1.10 (1.03--1.18)   0.036
   Adj PR (95% CI)         1 (Ref)                                                          1.01 (0.95--1.07)   1.02 (0.96--1.09)   0.98 (0.92--1.04)   1.03 (0.96--1.10)   0.653
                                                                                                                                                                            
  Phthalates                                                                                                                                                                
  High MWP                                                                                                                                                                  
   Quintile median μg/gC   84                                                               138                 204                 326                 616                 
   *n* B2+/total           67/196                                                           62/197              53/196              40/197              75/196              
   PR (95% CI)             1 (Ref)                                                          0.98 (0.91--1.05)   0.95 (0.88--1.02)   0.90 (0.84--0.96)   1.03 (0.96--1.10)   0.716
   Adj PR (95% CI)         1 (Ref)                                                          0.98 (0.92--1.04)   0.98 (0.92--1.04)   0.94 (0.88--1.00)   1.03 (0.97--1.10)   0.781
  Low MWP                                                                                                                                                                   
   Quintile median μg/gC   66                                                               112                 173                 272                 721                 
   *n* B2+/total           46/196                                                           54/197              55/196              64/197              78/196              
   PR (95% CI)             1 (Ref)                                                          1.03 (0.96--1.11)   1.04 (0.97--1.11)   1.07 (1.00--1.15)   1.13 (1.06--1.21)   0.000
   Adj PR (95% CI)         1 (Ref)                                                          1.03 (0.97--1.09)   1.01 (0.95--1.07)   1.04 (0.98--1.11)   1.06 (0.99--1.14)   0.087
                                                                                                                                                                            
  Phytoestrogens                                                                                                                                                            
  Daidzein                                                                                                                                                                  
   Quintile median μg/gC   20                                                               48                  104                 281                 1,359               
   *n* B2+/total           59/196                                                           65/197              67/197              58/196              47/196              
   PR (95% CI)             1 (Ref)                                                          1.02 (0.95--1.10)   1.03 (0.96--1.10)   1.00 (0.93--1.07)   0.95 (0.89--1.02)   0.121
   Adj PR (95% CI)         1 (Ref)                                                          1.05 (0.99--1.11)   1.02 (0.96--1.08)   1.00 (0.94--1.06)   0.96 (0.90--1.02)   0.061
  Genistein                                                                                                                                                                 
   Quintile median μg/gC   9.4                                                              20                  45                  127                 610                 
   *n* B2+/total           62/196                                                           65/197              65/196              54/197              50/196              
   PR (95% CI)             1 (Ref)                                                          1.01 (0.94--1.08)   1.01 (0.94--1.08)   0.97 (0.90--1.04)   0.95 (0.89--1.02)   0.081
   Adj PR (95% CI)         1 (Ref)                                                          1.02 (0.96--1.08)   1.00 (0.94--1.06)   0.97 (0.91--1.03)   0.97 (0.92--1.03)   0.103
  Enterolactone                                                                                                                                                             
   Quintile median μg/gC   97                                                               283                 522                 899                 1,922               
   *n* B2+/total           66/196                                                           62/197              66/196              57/197              45/196              
   PR (95% CI)             1 (Ref)                                                          0.98 (0.92--1.05)   1.00 (0.93--1.07)   0.96 (0.90--1.03)   0.92 (0.86--0.99)   0.018
   Adj PR (95% CI)         1 (Ref)                                                          1.02 (0.96--1.08)   1.03 (0.97--1.09)   1.00 (0.94--1.07)   1.03 (0.97--1.10)   0.462
                                                                                                                                                                            
  Pubic hair development                                                                                                                                                    
  Phenols                                                                                                                                                                   
  BP3                                                                                                                                                                       
   Quintile median μg/gC   3.7                                                              11                  30                  94                  853                 
   *n* PH2+/*n* total      48/195                                                           54/195              40/191              35/194              33/189              
   PR (95% CI)             1 (Ref)                                                          1.02 (0.96--1.10)   0.97 (0.91--1.04)   0.95 (0.89--1.01)   0.94 (0.88--1.01)   0.01
   Adj PR (95% CI)         1 (Ref)                                                          1.06 (1.00--1.14)   1.02 (0.96--1.09)   1.02 (0.95--1.09)   1.06 (0.98--1.15)   0.40
  BPA                                                                                                                                                                       
   Quintile median μg/gC   1.0                                                              1.6                 2.4                 3.8                 8.8                 
   *n* PH2+/total          39/194                                                           44/196              52/190              38/191              37/193              
   PR (95% CI)             1 (Ref)                                                          1.02 (0.95--1.09)   1.06 (0.99--1.14)   1.00 (0.93--1.07)   0.99 (0.93--1.06)   0.67
   Adj PR (95% CI)         1 (Ref)                                                          1.03 (0.96--1.09)   1.06 (0.99--1.13)   0.99 (0.92--1.05)   1.00 (0.94--1.07)   0.57
  2,5-DCP                                                                                                                                                                   
   Quintile median μg/gC   1.6                                                              4.0                 11                  37                  179                 
   *n* PH2+/total          32/189                                                           32/192              40/195              57/194              49/194              
   PR (95% CI)             1 (Ref)                                                          1.00 (0.94--1.06)   1.03 (0.97--1.10)   1.11 (1.03--1.18)   1.07 (1.00--1.15)   0.00
   Adj PR (95% CI)         1 (Ref)                                                          0.95 (0.89--1.02)   0.95 (0.89--1.02)   1.00 (0.92--1.08)   0.93 (0.86--1.01)   0.40
  Triclosan                                                                                                                                                                 
   Quintile median μg/gC   2.6                                                              6.9                 15                  38                  170                 
   *n* PH2+/total          56/191                                                           37/192              44/192              32/195              41/194              
   PR (95% CI)             1 (Ref)                                                          0.92 (0.86--0.99)   0.95 (0.89--1.02)   0.90 (0.84--0.96)   0.94 (0.87--1.00)   0.06
   Adj PR (95% CI)         1 (Ref)                                                          0.93 (0.87--0.99)   0.93 (0.87--0.99)   0.89 (0.83--0.94)   0.94 (0.88--1.00)   0.02
  Paraben sum                                                                                                                                                               
   Quintile median μg/gC   15                                                               436                 84                  197                 837                 
   *n* PH2+/total          33/178                                                           25/177              37/178              44/174              50/179              
   PR (95% CI)             1 (Ref)                                                          0.96 (0.90--1.03)   1.02 (0.95--1.09)   1.06 (0.98--1.13)   1.08 (1.01--1.16)   0.00
   Adj PR (95% CI)         1 (Ref)                                                          0.94 (0.89--1.01)   0.95 (0.89--1.02)   1.02 (0.96--1.10)   0.97 (0.90--1.04)   0.80
                                                                                                                                                                            
  Phthalates                                                                                                                                                                
  High MWP                                                                                                                                                                  
   Quintile median μg/gC   84                                                               138                 203                 327                 613                 
   *n* PH2+/total          55/193                                                           44/195              37/191              35/192              39/193              
   PR (95% CI)             1 (Ref)                                                          0.95 (0.89--1.02)   0.93 (0.87--0.99)   0.92 (0.86--0.98)   0.94 (0.87--1.00)   0.04
   Adj PR (95% CI)         1 (Ref)                                                          0.98 (0.92--1.04)   0.95 (0.90--1.01)   0.95 (0.89--1.01)   0.94 (0.88--1.00)   0.04
  Low MWP                                                                                                                                                                   
   Quintile median μg/gC   66                                                               112                 173                 272                 718                 
   *n* PH2+/total          30/190                                                           30/192              50/194              44/195              56/193              
   PR (95% CI)             1 (Ref)                                                          1.00 (0.94--1.06)   1.09 (1.02--1.16)   1.06 (0.99--1.13)   1.11 (1.04--1.19)   0.00
   Adj PR (95% CI)         1 (Ref)                                                          1.00 (0.94--1.06)   1.05 (0.98--1.12)   1.03 (0.97--1.10)   1.06 (0.98--1.13)   0.08
                                                                                                                                                                            
  Phytoestrogens                                                                                                                                                            
  Daidzein                                                                                                                                                                  
   Quintile median μg/gC   20                                                               48                  104                 281                 1,347               
   *n* PH2+/total          49/195                                                           46/192              39/196              31/190              44/191              
   PR (95% CI)             1 (Ref)                                                          0.99 (0.92--1.06)   0.96 (0.90--1.02)   0.93 (0.87--0.99)   0.98 (0.92--1.05)   0.18
   Adj PR (95% CI)         1 (Ref)                                                          1.01 (0.95--1.08)   0.97 (0.91--1.03)   0.95 (0.89--1.01)   1.00 (0.94--1.07)   0.39
  Genistein                                                                                                                                                                 
   Quintile median μg/gC   9.5                                                              20                  46                  129                 607                 
   *n* PH2+/total          48/193                                                           45/194              45/193              26/194              45/190              
   PR (95% CI)             1 (Ref)                                                          0.99 (0.92--1.06)   0.99 (0.92--1.06)   0.91 (0.85--0.97)   0.99 (0.92--1.06)   0.19
   Adj PR (95% CI)         1 (Ref)                                                          1.00 (0.94--1.06)   1.01 (0.95--1.07)   0.93 (0.88--0.99)   1.03 (0.96--1.09)   0.76
  Enterolactone                                                                                                                                                             
   Quintile median μg/gC   97                                                               282                 522                 899                 1,832               
   *n* PH2+/total          45/195                                                           37/193              48/194              40/195              39/187              
   PR (95% CI)             1 (Ref)                                                          0.97 (0.91--1.04)   1.01 (0.95--1.09)   0.98 (0.92--1.05)   0.98 (0.92--1.05)   0.77
   Adj PR (95% CI)         1 (Ref)                                                          0.99 (0.93--1.05)   1.02 (0.96--1.08)   0.98 (0.92--1.05)   1.03 (0.96--1.10)   0.47

Abbreviations: Adj, adjusted; C, creatinine; Ref, referent. Adjusted models included age, race/ethnicity, sex- and age-specific BMI% ([@b4-ehp-118-1039]), guardian education, season of urine collection, and site. There were fewer paraben measurements than other biomarkers because they were not measured early in the study. Quintile cut points were based on 982 girls with breast stage data, biomarkers, and creatinine. Quintile medians are among girls with breast or pubic stages. Breast stages were available for 981 girls with all biomarkers (963 for pubic hair); one additional girl with phthalate/phenol biomarkers was B1, PH2+ (982 total breast, 964 PH); one additional girl with phytoestrogens was B2+, PH1 (982 total breast, 964 PH stages).

###### 

Adjusted PRs (95% CIs) for any breast development stage (B2+ vs. B1) at visit 2 in relation to urinary environmental biomarkers and age-specific BMI measured at visit 1.

                                                                                            Urinary enterolactone quintile \[median creatinine (C) corrected biomarker concentration (μg/gC) for quintile\]                                                                                   
  ----------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------- ------------------- ------------------- ------------------- ------------------- --------
  *n* B2+ / *n* total                                                                       12/84                                                                                                             14/82               17/99               20/102              27/124              
   Adjusted PR (95% CI) among low-BMI girls (BMI% range, \< 1 to 68%; median = 36.0%)       1.0 (ref)                                                                                                         1.06 (0.96--1.15)   1.05 (0.96--1.15)   1.11 (1.01--1.22)   1.15 (1.05--1.26)   0.0016
  *n* B2+ / *n* total                                                                       54/112                                                                                                            48/115              49/97               37/95               18/72               
   Adjusted PR (95% CI) among high-BMI girls (BMI% range, 68.5 to \> 99%; median = 90.1%)   1.34 (1.23--1.45)                                                                                                 1.30 (1.20--1.42)   1.35 (1.24--1.48)   1.24 (1.13--1.36)   1.21 (1.10--1.33)   0.0105

PRs were computed from model with interaction term (ordinal values of enterolactone biomarker quintiles times 2-level BMI), adjusted for age at visit 2, race/ethnicity, site, caregiver education, season of urine collection. *p*-Interaction = 0.0006.

[^1]: L.H.K. is employed by Kaiser Permanente. The remaining authors declare they have no actual or potential competing financial interests.
